Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-547,632 in Recurrent Ovarian Cancer
NCT00074867Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of CP-547632 in epithelial ovarian cancer (EOC), primary peritoneal serous carcinoma (PPSC) and fallopian tube cancer (PFTC), sponsored by Pfizer. Primary endpoint: Objective Response Criteria. Started Oct 2003; status: completed.
02
Drugs
CP-547632
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal serous carcinoma (PPSC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00074867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00074867.